Method for measuring bone loss rate

Patent metadata

Field	Value
Publication number	US-9988682-B2
Application number	US-201414765782-A
Country	US
Kind code	B2
Filing date	Feb 7, 2014
Priority date	Feb 8, 2013
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

The present invention relates to a method for diagnosing bone loss rate, particularly in the field of bone anchored implants. The present patent provides with a method that comprises the steps of: a) quantifying the expression level of one or more markers or ratio thereof related to the activity of osteoclasts and/or osteoblasts in an ex vivo sample; and b) determining the bone loss rate as a function of ongoing loss of marginal bone level by interpolating the value obtained in step a) in one or more calibration curves. The invention also relates to a kit for performing said method.

First claim

The invention claimed is:

1. A method of measuring bone loss rate and treating periodontal or peri-implant disease in a subject, wherein the method comprises the steps of:
a) obtaining a value of an expression level of one or more markers or ratio thereof related to activity of at least one of osteoclasts or osteoblasts in an ex vivo gingival or peri-implant crevicular fluid sample obtained from a subject to determine if the subject has periodontal or peri-implant disease,
wherein the one or more markers or ratio thereof comprises a marker or ratio thereof selected from the group consisting of tartrate-resistant acid phosphatase (TRAP), TRAP/osteocalcin ratio, CatK/osteocalcin ratio, and osteoprotegerin (OPG);

b) determining the bone loss rate of the subject as a function of ongoing loss of marginal bone level by interpolating the value obtained in step a) in one or more calibration curves; and
c) treating the subject based on the determined bone loss rate of the subject, the treatment comprising a surgical treatment when the determined bone loss rate is higher than 2.0 mm/year.

2. The method according to claim 1 , wherein said value is obtained by nucleic acid quantification.

3. The method according to claim 2 , wherein said quantification is performed by at least one of qPCR or Northern Blot.

4. The method according to claim 1 , wherein said one or more calibration curves provide a linear relationship, a quadratic relationship, a cubic relationship, quartic relationship, quantic relationship, exponential relationship, or logarithmic relationship between the bone loss rate and the expression level of one of more markers or ratio of markers or combinations thereof.

5. The method according to claim 4 , wherein said one or more calibration curves provides a linear relationship between the bone loss rate and the expression level of one or more markers or ratio of markers or combinations thereof.

6. The method according to claim 1 , wherein said subject is treated for peri-implant disease.

7. The method according to claim 1 , wherein said subject is treated for periodontal disease.

8. The method according to claim 1 , wherein the treatment comprises oral hygiene treatment and a maintenance program when the determined bone loss rate is 0.2 mm/year or lower.

9. The method according to claim 1 , wherein the treatment comprises oral hygiene treatment, a maintenance program and a follow up visit when the determined bone loss rate is within the range of 1 to 1.5 mm/year.

Assignees

• Nobel Biocare Services Ag

Inventors

• Hall Jan

Classifications

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title